Objective To investigate the expression and clinical significance of miR-483-3p in patients with gesta-tional diabetes mellitus(GDM).Methods A total of 100 GDM patients with 24-32 weeks of gestation who under-went routine obstetric examination in Anqiu People's Hospital were selected as the normal glucose tolerance(NGT)group,and a total of 98 healthy pregnant women of the same age of 24-32 gestational weeks were selected as the NGT group.The expression level of miR-483-3p was detected by RT-qPCR,the diagnostic value of miR-483-3p in GDM was analyzed by receiver operating characteristic(ROC)curve,the correlation between the expression levels of miR-483-3p and clinical indicators in the GDM group was analyzed by chi-square test,and the risk factors of GDM were analyzed by Logistic regression.Dual luciferase reporter gene assay was used to verify the targeting relationship between miR-483-3p and autophagy-related protein 7(ATG7).CCK8,flow cytometry and Transwell assays were used to detect the proliferation,apoptosis,and migration and invasion ability of cells,respectively.Results The expression level of miR-483-3p in the serum of patients in the GDM group was significantly higher than that in the NGT group.The expression of miR-483-3p had diagnostic value for GDM.Pre-pregnancy BMI,FBG,FINS,HOMA-IR and TG were significantly correlated with serum miR-483-3p expression.In addition,BMI and TG before pregnancy were risk factors leading to GDM.miR-483-3p regulated HG-treated HTR-8/SVneo cell proliferation,apoptosis,migration and invasion by targeting at ATG7.Conclusions miR-483-3p is involved in the disease pro-gression of GDM and is a potential biomarker of GDM diagnosis.

OBJECTIVE： To systematically evaluate the efficacy and safety of Endostar combined with gemcitabine and cisplatin in the treatment of non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use. METHODS： Retrieved from Cochrane Library， PubMed， Embase， ClinicalTrials， CNKI， Wanfang and VIP database， randomized controlled trials （RCT） about Endostar combined with gemcitabine and cisplatin（trial  group） vs. gemcitabine combined with cisplatin （control group） for NSCLC were collected. After literature screening， data extraction and quality evaluation with Cochrane 5.1.0 bias risk evaluation tool and Jadad scale， Meta-analysis was performed by using Rev Man 5.3 software. RESULTS： A total of 27 RCTs were included， involving 1 646 patients. Results of Meta-analysis showed that response rate [RR＝1.67， 95％CI（1.48，1.89），P＜0.000 01] and clinical benefit rate [RR＝1.26， 95％CI （1.20， 1.33），P＜0.000 01] of trial group were significantly higher than those of control group. There was no statistical significance in the incidence of leucopenia [RR＝0.98，95％CI（0.88， 1.11），P＝0.79]， thrombocytopenia [RR＝1.07， 95％CI（0.91， 1.26），P＝0.39] and gastrointestinal reaction [RR＝1.01， 95％CI（0.90， 1.14），P＝0.85] between 2 groups. CONCLUSIONS： Endostar combined with gemcitabine and cisplatin can improve therapeutic efficacy of NSCLC patients， without increasing the incidence of ADR.